A Review on Amyloid Beta Peptides and Tau Proteins Involved in the Alzheimer’s Disease

Authors
Masoud Soheili
Leyla Ara
Seyyed Mojtaba Bani Taba Bidgoli
Mahmoud Salami
Abstract
Alzheimer’s disease as a neurodegenerative disorder is known as a main cause of cognitive problems including learning and memory. Indeed, more than half of people with senile dementia suffer from the disease. The Alzheimer’s disease is resulted from numerous factors such as biochemical disorders in protein production, uncontrolled electrical activity of neurons and changes in level of some key neurotransmitters in the brain. Oxidative stresses, increased glutamate dependent neurotoxicity, decreased release of acetyl choline and inflammation of the brain tissue are the main factors involving in the Alzheimer’s disease. However, abnormal forms of amyloid beta peptides as well as tau proteins have key role in emergence of the disease. The present study reviews the critical involvement of amyloid beta peptides and tau proteins in modification of neuronal function leading to the Alzheimer’s disease.
Keywords
Alzheimer’s disease
Amyloid beta
Tao proteins
Dementia
Akram M, Nawaz A. Effects of medicinal plants on Alzheimer's disease and memory deficits. Neural Regen Res 2017; 12(4):660-70.
Capucho PHFV, Brucki SMD. Judgment in mild cognitive impairment and Alzheimer's disease. Dement Neuropsychol 2011; 5(4):297-302.
Avila J, Llorens-Martin M, Pallas-Bazarra N, Bolos M, Perea JR, Rodriguez-Matellan A, et al. Cognitive decline in neuronal aging and Alzheimer's disease: Role of NMDA receptors and associated proteins. Front Neurosci 2017; 11:626.
Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018; 14:450-64.
Glynn-Servedio BE, Ranola TS. AChE inhibitors and NMDA receptor antagonists in advanced Alzheimer's disease. Consult Pharm 2017; 32(9):511-8.
Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A. Amyloid beta, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? CNS Neurosci Ther 2013; 19(8):549-55.
Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017; 52:196-213.
Lue LF, Guerra A, Walker DG. Amyloid Beta and Tau as Alzheimer's disease blood biomarkers: Promise from new technologies. Neurol Ther 2017; 6(Suppl 1):25-36.
Soheili M, Tavirani MR, Salami M. Clearance of Amyloid Beta Plaques from brain of alzheimeric rats by Lavandula angustifolia. Neuroscience & Medicine. 2012;Vol.03No.04:6.
Parsons CG, Rammes G. Preclinical to phase II amyloid beta (Abeta) peptide modulators under investigation for Alzheimer's disease. Expert Opin Investig Drugs. 2017; 26(5):579-92.
Brody DL, Jiang H, Wildburger N, Esparza TJ. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. Alzheimers Res Ther 2017; 9(1):62.
Leal NS, Schreiner B, Pinho CM, Filadi R, Wiehager B, Karlstrom H, et al. Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid beta-peptide production. J Cell Mod Med 2016; 20(9):1686-95.
Takasugi N, Sasaki T, Shinohara M, Iwatsubo T, Tomita T. Synthetic ceramide analogues increase amyloid-beta 42 production by modulating gamma-secretase activity. Biochemical and biophysical research communications 2015; 457(2):194-9.
Albani D, Roiter I, Artuso V, Batelli S, Prato F, Pesaresi M, et al. Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiol Aging 2007; 28(11):1682-8.
Yang X, Yang Y, Li G, Wang J, Yang ES. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci 2008; 34(2):165-71.
Davis J, Couch R. Strategizing the development of Alzheimer’s therapeutics. Advances in Alzheimer’s disease 2014; 3(3):107-27.
Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 2017.
Cooper EL, Ma MJ. Alzheimer Disease: Clues from traditional and complementary medicine. Journal of traditional and complementary medicine 2017; 7(4):380-5.
Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2015; 96(Pt B):255-62.
Valles AS, Borroni MV, Barrantes FJ. Targeting brain alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status. CNS Drugs 2014; 28(11):975-87.
Salgado-Puga K, Pena-Ortega F. Cellular and network mechanisms underlying memory impairment induced by amyloid beta protein. Protein Pept Lett 2015; 22(4):303-21.
Salazar SV, Strittmatter SM. Cellular prion protein as a receptor for amyloid-beta oligomers in Alzheimer's disease. Biochem Biophys Res Commun 2017; 483(4):1143-7.
Walker LC, Schelle J, Jucker M. The Prion-Like properties of Amyloid-beta assemblies: Implications for Alzheimer's disease. Cold Spring Harb Perspect Med 2016; 6(7).
Zhang Y, Li P, Feng J, Wu M. Dysfunction of NMDA receptors in Alzheimer's disease. Neurol Sci 2016; 37(7):1039-47.
Majlath Z, Toldi J, Vecsei L. The potential role of kynurenines in Alzheimer's disease: Pathomechanism and therapeutic possibilities by influencing the glutamate receptors. J Neural Transm (Vienna) 2014; 121(8):881-9.
Foster TC, Kyritsopoulos C, Kumar A. Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer's disease. Behav Brain Res 2017; 322(Pt B):223-32.
Mroczko B, Groblewska M, Litman-Zawadzka A, Kornhuber J, Lewczuk P. Amyloid β oligomers (AbetaOs) in Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria 2017; 125(2):177-91.
Doost mohammad pour J, Hosseinmardi N, Janahmadi M, Ebrahimi S, Fathollahi Y, Motamedi F. Induction of a rat model of Alzheimer’s disease by amyloid-β did not change short term synaptic plasticity in CA1 area of hippocampus. koomesh 2014; 16(1):76-81. [Persian]
Rub U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW. Alzheimer's disease: Characterization of the brain sites of the initial tau cytoskeletal pathology will improve the success of novel immunological anti-tau treatment approaches. J Alzheimers Dis 2017; 57(3):683-96.
Soheili M, Rezaei Tavirany M, Salami M. Lavandula angustifolia extract improves deteriorated synaptic plasticity in an animal model of Alzheimer’s disease. Iran J Basic Med Sci 2015; 18(11):1147-52.
Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014; 82(4):756-71.
Del Campo M, Stargardt A, Veerhuis R, Reits E, Teunissen CE. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Abeta by insulin degrading enzyme (IDE) in Alzheimer's disease. Neurosci Lett 2015; 589:47-51.
Taghizadeh M, Talaei SA, Djazayeri A, Salami M. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease. Nutr Neurosci 2014; 17(4):172-7.
Soheili M, Salami M, Haghir A, Zali H, Rezaei Tavirani M. Aqueous extract of lavandula angustifolia alter protein expression in Alzheimer rats. Journal of Reports in Pharmaceutical Sciences 2014; 3(1):1-9.
Wood H. Alzheimer disease: Scanning ultrasound elicits amyloid-beta clearance in mice. Nat Rev Neurol 2015; 11(5):247.
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106(12):1489-99.
Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, et al. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res 2002; 43(1):39-56.
Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, et al. Peripheral delivery of a CNS targeted, metalo-protease reduces abeta toxicity in a mouse model of Alzheimer's disease. PLoS One 2011; 6(1):e16575.
van Dyck CH. Anti-Amyloid-beta monoclonal antibodies for Alzheimer's disease: Pitfalls and promise. Biol Psychiatry 2017; 83(4):311-19
Tascone LDS, Bottino CMC. Neurobiology of neuropsychiatric symptoms in Alzheimer's disease: A critical review with a focus on neuroimaging. Dement Neuropsychol 2013; 7(3):236-43.
Tracy TE, Gan L. Acetylated tau in Alzheimer's disease: An instigator of synaptic dysfunction underlying memory loss: Increased levels of acetylated tau blocks the postsynaptic signaling required for plasticity and promotes memory deficits associated with tauopathy. Bioessays. 2017;39(4).
Mahajan D, Votruba M. Can the retina be used to diagnose and plot the progression of Alzheimer's disease? Acta Ophthalmol 2017; 95(8):768-77.
Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 3:Cd010803.
Heinisch JJ, Brandt R. Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells. Microb Cell 2016; 3(4):135-46.
Kontaxi C, Piccardo P, Gill AC. Lysine-Directed Post-translational modifications of tau protein in Alzheimer's disease and related tauopathies. Front Mol Biosci 2017; 4:56.
de Paula VJR, Guimaraes FM, Diniz BS, Forlenza OV. Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both? Dement Neuropsychol 2009; 3(3):188-94.
Ma RH, Zhang Y, Hong XY, Zhang JF, Wang JZ, Liu GP. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease. J Huazhong Univ Sci Technolog Med Sci. 2017;37(3):307-12.
Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: Triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol 2016; 160:134-47.
Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer's disease genetic risk factor APOE-epsilon4 also affects normal brain function. Curr Alzheimer Res 2016; 13(11):1200-7.
Chang TY, Chang C. ApoE and lipid homeostasis in Alzheimer's disease: Introduction to the thematic review series. J Lipid Res 2017; 58(5):823.
Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. J Lipid Res 2017; 58(5):824-36.
Ba M, Kong M, Li X, Ng KP, Rosa-Neto P, Gauthier S. Is ApoE varepsilon 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener 2016; 5:20.